In a groundbreaking development for male contraception, DNA Diagnostics Center (DDC) has announced a strategic partnership with Contraline, a clinical-stage medical device company. Together, they are spearheading the ADAM™ clinical trial, which aims to introduce a revolutionary non-hormonal contraceptive device for men.
A Breakthrough in Male Contraception
The ADAM™ device represents a significant advancement in reproductive health. Unlike traditional methods such as condoms and vasectomy, ADAM™ involves injecting a proprietary hydrogel into the vas deferens, the duct that conveys sperm from the testicle to the urethra. This hydrogel blocks sperm transport, similar to a vasectomy, but with the notable advantage of being non-permanent and easier to reverse. This innovative approach provides men with a long-lasting contraceptive solution without the need for hormonal interventions.
Clinical Trials and Global Collaboration
The first-in-human trial of ADAM™ is being conducted in Australia, where 25 patients have been enrolled. The trial is now focused on monitoring the long-term safety and efficacy of the device. In a move that underscores the importance of accurate and convenient fertility testing, Contraline has integrated DDC’s SpermCheck Vasectomy® into the ADAM™ Study protocol. This at-home test kit allows men to confirm the success of the contraceptive device by detecting the presence of sperm in semen samples.
Enhancing User Convenience
SpermCheck Vasectomy® is widely recognized as a leading male fertility brand in the United States, with over one million units sold. Its inclusion in the ADAM™ trial offers participants a reliable and accessible method to monitor the effectiveness of the contraceptive device from the privacy of their own homes. Kevin Eisenfrats, co-founder and CEO of Contraline, highlighted the synergy between the two products, noting that this integration will provide users with immediate feedback on the efficacy of ADAM™.
Commitment to Reproductive Health
This collaboration between DNA Diagnostics Center and Contraline exemplifies their shared commitment to advancing male contraception and improving reproductive health outcomes. Both companies are dedicated to providing innovative solutions that address the unmet needs in the field of reproductive health.
About the Partners
DNA Diagnostics Center (DDC): A global leader in DNA and personal health testing, DDC offers comprehensive services for paternity and family relationships, fertility, lifestyle, veterinary, and consumer health. DDC is part of the Eurofins network of laboratories, which operates over 900 labs in more than 60 countries.
Contraline: Founded in 2015, Contraline is a clinical-stage medical device company focused on reproductive health innovation. The company’s flagship product, ADAM™, is the world’s first hydrogel designed to provide long-lasting, non-hormonal, and reversible contraception for men. Contraline is based in Charlottesville, Virginia.
